Freeze dried kit formulation of trastuzumab-immunoconjugates by Sterjova, Marija et al.
FREEZE DRIED KIT FORMULATION OF TRASTUZUMAB 
IMMUNOCONJUGATES
Marija Sterjova, Emilija Janevik-Ivanovska, Paulina Apostolova, Predrag Dzodic
Trastuzumab:
 Humanized IgG1 monoclonal antibody.
 Selective and specific therapy (HER2 positive breast cancer).
 Conjugation with another dugs, toxins and radioisotopes.
 Synthetized many stable conjugates with BFCA (p-SCN-Bn-DTPA, p-SCN-Bn-
DOTA, 1B4M-DTPA) for further labeling with radioisotopes.
.
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The binding is via thiourea linkage between amine groups of
lysine residues of trastuzumab and isothiocyanato groups of
chelators.
Obtained stable, homogeneous cakes with flat surfaces.
After reconstitution with 0,9 % NaCl → clear to opalescent
solutions without presence of visible solid particles and colloids.
After complete freeze drying the vials were closed and kept at 4°C for 
following examinations and protein characterization with SDS-PAGE, 
IR, RAMAN, MALDI-TOF and for further labeling with radioisotopes 
(Lu-177 and Y-90).   
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Trastuzimab - purified from Herceptin® with six cycles of
ultrafiltration (0.1M PBS, pH=8).
Mixing the antibody with 10 mg/ml solution of BFCAs in different
ratio (p-SCN-Bn-DTPA – 1:10; 1:20; 1:50, 1B4M-DTPA – 1:10;
1:20; 1:50, p-SCN-Bn-DOTA – 1:20)
 18 hours incubation on 4°C with gentle shaking.
 Immunoconjugates - purified with six cycles of ultrafiltration and
adjusted to concentration of 1 mg/ml.
Trastuzumab immunoconjugates - lyophilized to solid states with
Labconco Free Zone Stoppering Tray Dryer.
